Athenex Annual Revenue, Number of Employees, Growth and Funding

Claim your profile


Buffalo, NY USA
Total Funding:$252M
Lead Investor(s):N/A
Claim your profile

Growjo 10k Ranking

Estimated Revenue & Financials

  • Athenex's estimated annual revenue is currently $42M per year.
  • Athenex received $100.0M in venture funding in July 2018.
  • Athenex's estimated revenue per employee is $187,540
  • Athenex's total funding is $252M.

Employee Data

  • Athenex has 224 Employees.
  • Athenex grew their employee count by 9% last year.
  • Athenex currently has 42 job openings.

Executive Contacts

James HusseyExecutive Vice President
Leanne KisickiDirector Of Quality Control
Sameer UrgaonkarAssociate Director of Chemistry
James ClementsDirector of Project Management
David CutlerVP Clinical Development
Karen GatewoodDirector, Corporate Contracting
Ann Choi-RoloffArea Sales Director
Tony GulczynskiVice President Alternative Customer Channels
Jonathan TurnquestDirector of Supply Chain & Logistics
Ulziihutag DarambazarDirector of Commercial Analytics

Athenex is a global specialty oncology pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies. The company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients. Our business includes medical technology innovation centers and a unique manufacturing supply chain across both China and North America. Through the connected innovation and manufacturing supply chain presence, we can identify, develop and deliver proprietary medical technology across continents and multiple regulatory environments.



Number of Employees


Revenue (est)


Current Jobs


Employee Growth %


Total Funding







NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Renaissance Pha...
Symbio Research
Innovation Asso...
Insight Strateg...
LI Script
Medical Knowled...
Everest Medicin...
CHDI Foundation

Athenex News

09/07/2019 - Athenex Announces Appointment of Daniel Lang MD to Lead ...

BUFFALO, N.Y., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the ...

09/08/2019 - Digging Up the Details on Athenex, Inc. (ATNX)

On Thursday, shares of Athenex, Inc. (NASDAQ:ATNX) marked $14.65 per share versus a previous $14.09 closing price. With having a 3.97% ...

08/13/2019 - Athenex: Latest Data Makes A Paradigm Shift In Current ...

Athenex reported positive results in a phase 3 study using oral paclitaxel to treat patients with metastatic breast cancer. The key advantage of ...

Athenex Funding

DateAmountRoundLead InvestorsReference
2018-01-23$UndisclosedUndisclosedDeutsche Bank SecuritiesArticle
2018-01-26$75.4MUndisclosedDeutsche Bank SecuritiesArticle
2018-07-03$100.0MUndisclosedPerceptive AdvisorsArticle

Athenex Executive Hires

2016-02-10Simon PedderVP Corporate Strategy/Business DevelopmentArticle
2016-04-05David CutlerVP Clinical DevelopmentArticle
2016-07-11James HusseyEVP Pharmaceutical DivisionArticle
2017-02-28Nick RiehleChief Financial OfficerArticle
2017-03-02Jeffrey YordonCOOArticle
2018-06-06Christina WangVP Clinical Operations and Corporate Development, Asia Pacific.Article
2018-08-21Randoll SzeCFOArticle